Targeting CLL-1 for acute myeloid leukemia therapy

por Ma, Hongbing, Padmanabhan, Iyer Swaminathan, Parmar, Simrit, Gong, Yuping
Publicado en J Hematol Oncol (2019)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

por Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Publicado 2013

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

por Coiffier, Bertrand, Pro, Barbara, Prince, H Miles, Foss, Francine, Sokol, Lubomir, Greenwood, Matthew, Caballero, Dolores, Morschhauser, Franck, Wilhelm, Martin, Pinter-Brown, Lauren, Padmanabhan Iyer, Swaminathan, Shustov, Andrei, Nielsen, Tina, Nichols, Jean, Wolfson, Julie, Balser, Barbara, Horwitz, Steven
Publicado 2014

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

por Jewell, Roxanne C., Kipps, Thomas J., Dürig, Jan, Griskevicius, Laimonas, Stilgenbauer, Stephan, Smolej, Lukáš, Mayer, Jiří, Hess, Georg, Hernandez-Ilizaliturri, Francisco J., Padmanabhan-Iyer, Swaminathan, Fang, Lei, Goldstein, Nancy, Gorczyca, Michele, Gupta, Ira, Lisby, Steen, Wierda, William G.
Publicado en Leuk Lymphoma (2016)

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

por Jewell, Roxanne C., Kipps, Thomas J., Dürig, Jan, Griskevicius, Laimonas, Stilgenbauer, Stephan, Smolej, Lukáš, Mayer, Jiří, Hess, Georg, Hernandez-Ilizaliturri, Francisco J., Padmanabhan-Iyer, Swaminathan, Fang, Lei, Goldstein, Nancy, Gorczyca, Michele, Gupta, Ira, Lisby, Steen, Wierda, William G.
Publicado en Leuk Lymphoma (2016)

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

por Sehn, Laurie H., Goy, Andre, Offner, Fritz C., Martinelli, Giovanni, Caballero, M. Dolores, Gadeberg, Ole, Baetz, Tara, Zelenetz, Andrew D., Gaidano, Gianluca, Fayad, Luis E., Buckstein, Rena, Friedberg, Jonathan W., Crump, Michael, Jaksic, Branimir, Zinzani, Pier Luigi, Padmanabhan Iyer, Swaminathan, Sahin, Deniz, Chai, Akiko, Fingerle-Rowson, Günter, Press, Oliver W.
Publicado en J Clin Oncol (2015)

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

por Kelly, Kevin R., Friedberg, Jonathan W., Park, Steven I., McDonagh, Kevin, Hayslip, John, Persky, Daniel, Ruan, Jia, Puvvada, Soham, Rosen, Peter, Padmanabhan Iyer, Swaminathan, Stefanovic, Alexandra, Bernstein, Steven H., Weitman, Steven, Karnad, Anand, Monohan, Gregory, VanderWalde, Ari, Mena, Raul, Schmelz, Monika, Spier, Catherine, Groshen, Susan, Venkatakrishnan, Karthik, Zhou, Xiaofei, Sheldon-Waniga, Emily, Leonard, E. Jane, Mahadevan, Daruka
Publicado en Clin Cancer Res (2018)